- Home
- SPRO vs NKSH Comparison
SPRO vs NKSH Comparison
Compare SPRO & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- NKSH
- Stock Information
- Founded
- SPRO 2013
- NKSH 1891
- Country
- SPRO United States
- NKSH United States
- Employees
- SPRO N/A
- NKSH N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- NKSH Major Banks
- Sector
- SPRO Health Care
- NKSH Finance
- Exchange
- SPRO Nasdaq
- NKSH Nasdaq
- Market Cap
- SPRO 164.4M
- NKSH 163.0M
- IPO Year
- SPRO 2017
- NKSH N/A
- Fundamental
- Price
- SPRO $2.91
- NKSH $29.84
- Analyst Decision
- SPRO Buy
- NKSH Strong Buy
- Analyst Count
- SPRO 4
- NKSH 1
- Target Price
- SPRO $5.00
- NKSH $38.00
- AVG Volume (30 Days)
- SPRO 1.6M
- NKSH 18.2K
- Earning Date
- SPRO 08-04-2025
- NKSH 08-13-2025
- Dividend Yield
- SPRO N/A
- NKSH 5.06%
- EPS Growth
- SPRO N/A
- NKSH N/A
- EPS
- SPRO N/A
- NKSH 1.38
- Revenue
- SPRO $44,584,000.00
- NKSH $46,211,000.00
- Revenue This Year
- SPRO N/A
- NKSH N/A
- Revenue Next Year
- SPRO N/A
- NKSH $5.93
- P/E Ratio
- SPRO N/A
- NKSH $21.57
- Revenue Growth
- SPRO N/A
- NKSH 2.21
- 52 Week Low
- SPRO $0.51
- NKSH $23.75
- 52 Week High
- SPRO $3.09
- NKSH $33.37
- Technical
- Relative Strength Index (RSI)
- SPRO 71.62
- NKSH 73.23
- Support Level
- SPRO $2.79
- NKSH $27.01
- Resistance Level
- SPRO $3.03
- NKSH $27.88
- Average True Range (ATR)
- SPRO 0.12
- NKSH 0.77
- MACD
- SPRO -0.08
- NKSH 0.37
- Stochastic Oscillator
- SPRO 43.75
- NKSH 98.84
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.